Apeloa Pharmaceutical Co

Apeloa Pharmaceutical Co Debt

The Debt of Apeloa Pharmaceutical Co (000739.SZ) as of Oct 23, 2026 is 1.51 B CNY. In the previous year, Debt was 897.86 M CNY — a change of 68.61% (higher).

Debt

1.51 BCNY

YoY

68.61%

Last updated:

In 2025, Apeloa Pharmaceutical Co's total debt was 1.51 B CNY, a 68.61% change from the 897.86 M CNY total debt recorded in the previous year.

The Apeloa Pharmaceutical Co Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
686.10 M CNY
Jan 1, 2019
122.00 M CNY
Jan 1, 2020
330.28 M CNY
Jan 1, 2021
460.36 M CNY
Jan 1, 2022
828.25 M CNY
Jan 1, 2023
830.98 M CNY
Jan 1, 2024
897.86 M CNY
Jan 1, 2025
1.51 B CNY
The Apeloa Pharmaceutical Co Debt history
YEARDebtYoY
1.51 BCNY+68.61%
897.86 MCNY+8.05%
830.98 MCNY+0.33%
828.25 MCNY+79.91%
460.36 MCNY+39.38%
330.28 MCNY+170.72%
122.00 MCNY-82.22%
686.10 MCNY-38.35%
1.11 BCNY-7.18%
1.20 BCNY+4.02%
1.15 BCNY+30.14%
885.77 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Apeloa Pharmaceutical Co Stock analysis

What does Apeloa Pharmaceutical Co do? Apeloa Pharmaceutical Co., Ltd. generates revenue through the research, development, and production of active pharmaceutical ingredient (API) intermediates, contract development and production services (CDMO), and preparations. The company’s main products include bulk drugs, intermediates, chemical preparations, and Chinese traditional medicine preparations such as ubenimex capsules, cefixime, and amantadine. These products are sold to both domestic and overseas markets, with the company distributing its offerings across these segments. The firm’s business model focuses on serving pharmaceutical manufacturers and healthcare providers through its comprehensive range of API intermediates and finished preparations. The company’s revenue streams are derived from the sale of bulk drugs, intermediates, and chemical preparations, alongside its Chinese traditional medicine preparations like ubenimex capsules and cefixime. These products are targeted at pharmaceutical manufacturers seeking API intermediates and finished drug formulations. Apeloa Pharmaceutical serves both domestic and international clients, with its products distributed in both markets. The company’s CDMO services further support clients in the development and production of pharmaceutical products. Apeloa Pharmaceutical’s core business involves the production and sale of API intermediates, bulk drugs, and various preparations, including traditional Chinese medicine products. The company’s main customers are pharmaceutical manufacturers and healthcare providers who require intermediates for drug manufacturing and finished preparations for market distribution. Its domestic and overseas market presence ensures a diversified revenue base, with products like ubenimex capsules and amantadine contributing to its product portfolio. Apeloa Pharmaceutical Co is one of the most popular companies on Eulerpool.

Debt Details

Understanding Apeloa Pharmaceutical Co's Debt Structure

Apeloa Pharmaceutical Co's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Apeloa Pharmaceutical Co's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Apeloa Pharmaceutical Co’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Apeloa Pharmaceutical Co’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Apeloa Pharmaceutical Co stock

Debt of Apeloa Pharmaceutical Co is 1.51 B CNY in 2025.

Debt of Apeloa Pharmaceutical Co changed from 897.86 M CNY to 1.51 B CNY, representing a 68.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt Apeloa Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

Debt's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Apeloa Pharmaceutical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Apeloa Pharmaceutical Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Apeloa Pharmaceutical Co